.jpg "Radius Health (NASDAQ: RDUS)")
Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on Radius Health (NASDAQ: RDUS) yesterday and set a price target of $58. The company’s shares closed yesterday at $31.77.
Goldstein observed:
“TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics.”
According to TipRanks.com, Goldstein ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.1% and a 37.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Karyopharm Therapeutics.
Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $50.50.
See today’s analyst top recommended stocks >>
Based on Radius Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $71.02 million. In comparison, last year the company had a GAAP net loss of $56.94 million.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Radius Health, Inc. engages in the discovery and development of therapeutics for the treatment of osteoporosis, oncology, and endocrine diseases. The firm’s lead product, abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.
